MA55895A - Compositions d'oxymétazoline et procédés de traitement de troubles oculaires - Google Patents

Compositions d'oxymétazoline et procédés de traitement de troubles oculaires

Info

Publication number
MA55895A
MA55895A MA055895A MA55895A MA55895A MA 55895 A MA55895 A MA 55895A MA 055895 A MA055895 A MA 055895A MA 55895 A MA55895 A MA 55895A MA 55895 A MA55895 A MA 55895A
Authority
MA
Morocco
Prior art keywords
oxymetazoline
compositions
methods
eye disorders
treating eye
Prior art date
Application number
MA055895A
Other languages
English (en)
Inventor
Tina Devries
David Jacobs
Original Assignee
Rvl Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rvl Pharmaceuticals Inc filed Critical Rvl Pharmaceuticals Inc
Publication of MA55895A publication Critical patent/MA55895A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/10—Bag-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MA055895A 2019-05-06 2020-05-05 Compositions d'oxymétazoline et procédés de traitement de troubles oculaires MA55895A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962844069P 2019-05-06 2019-05-06
US201962843819P 2019-05-06 2019-05-06
US16/716,014 US10799481B1 (en) 2019-05-06 2019-12-16 Compositions and methods for treating ocular disorders
US16/715,998 US10814001B1 (en) 2019-05-06 2019-12-16 Oxymetazoline compositions

Publications (1)

Publication Number Publication Date
MA55895A true MA55895A (fr) 2022-03-16

Family

ID=72750169

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055895A MA55895A (fr) 2019-05-06 2020-05-05 Compositions d'oxymétazoline et procédés de traitement de troubles oculaires

Country Status (17)

Country Link
US (11) US10799481B1 (fr)
EP (1) EP3965737A1 (fr)
JP (2) JP7141420B2 (fr)
KR (3) KR102410503B1 (fr)
CN (2) CN117045596A (fr)
AU (1) AU2020268329A1 (fr)
BR (1) BR112021022404A2 (fr)
CA (1) CA3139443A1 (fr)
CL (1) CL2021002918A1 (fr)
CO (1) CO2021015265A2 (fr)
IL (1) IL287831A (fr)
MA (1) MA55895A (fr)
MX (1) MX2021013516A (fr)
PE (1) PE20220384A1 (fr)
SG (1) SG11202112272TA (fr)
WO (1) WO2020227260A1 (fr)
ZA (1) ZA202108950B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120225918A1 (en) * 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
US20240156786A1 (en) 2021-03-03 2024-05-16 Voom, Llc Compositions and methods for treatment of blepharitis
WO2023079427A1 (fr) * 2021-11-03 2023-05-11 Avaca Pharma Private Limited Compositions ophtalmiques et procédés associés

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE51421B1 (en) 1980-08-01 1986-12-24 Smith & Nephew Ass Ophthalmic compositions containing triamterene
US5459133A (en) 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
US5888493A (en) 1996-12-05 1999-03-30 Sawaya; Assad S. Ophthalmic aqueous gel formulation and related methods
DE10337186A1 (de) * 2003-08-13 2005-03-17 Merck Patent Gmbh Wässrige Wirkstoff-Lösung
US7812049B2 (en) 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
JP2006131628A (ja) * 2004-10-08 2006-05-25 Rohto Pharmaceut Co Ltd オキシメタゾリン含有水性組成物
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
AU2007227091B2 (en) 2006-03-17 2013-02-07 Johnson & Johnson Vision Care, Inc. Stabilized ophthalmic compositions comprising oxidatively unstable components
AU2007243334A1 (en) 2006-04-26 2007-11-08 Aciex Therapeutics, Inc. Compositions for the treatment and prevention of eyelid swelling
US8466203B2 (en) * 2006-12-06 2013-06-18 David Choohyun Paik Method of stabilizing human eye tissue by reaction with nitrite and related agents such as nitro compounds
US20090281156A1 (en) * 2007-12-21 2009-11-12 Schering-Plough Healthcare Products, Inc, Enhancing photostabilization of oxymetazoline
SI2262506T1 (sl) * 2008-03-11 2014-07-31 Alcon Research, Ltd. Močno flokulirane suspenzije triamcinolon acetonida z nizko viskoznostjo za intravitrealno injekcijo
EP2437602A4 (fr) * 2009-06-05 2014-02-19 Aciex Therapeutics Inc Formulations ophtalmiques, procédés pour les fabriquer et procédés pour les utiliser
US20120082625A1 (en) 2010-09-28 2012-04-05 Michael Graeber Combination treatment for rosacea
AU2011327785A1 (en) * 2010-11-08 2013-03-07 Healor Ltd. Buffered ophthalmic compositions and methods of use thereof
AU2011336449B2 (en) 2010-12-03 2016-07-07 Epi Health, Llc Pharmaceutical cream compositions comprising oxymetazoline
US20120225918A1 (en) 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
WO2013177594A2 (fr) 2012-05-25 2013-11-28 Xlear, Inc. Compositions anti-muqueuses à base de xylitol, procédés afférents et compositions afférentes
UA119324C2 (uk) 2013-04-02 2019-06-10 Теміс Медікер Лімітед Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні
EP3047712B1 (fr) 2013-09-18 2021-04-21 Mycronic AB Procédé, système et dispositif de manipulation de palettes dans un système smt
ES2796871T3 (es) 2014-06-11 2020-11-30 Epi Health Llc Formulaciones de oximetazolina estabilizadas y sus usos
US11052094B2 (en) 2015-05-29 2021-07-06 Sydnexis, Inc. D2O stabilized pharmaceutical formulations
US20170312335A1 (en) * 2015-12-30 2017-11-02 Lubris Llc Topical use of prg4 for treatment of allergy and symptoms of inflammation
WO2017132410A1 (fr) 2016-01-26 2017-08-03 Frank Litvack Compositions et utilisations d'agents alpha-adrénergiques
CN105997856A (zh) * 2016-06-24 2016-10-12 魏威 盐酸羟甲唑啉滴眼液及其制备方法
US11246816B2 (en) 2016-06-30 2022-02-15 The Procter And Gamble Company Shampoo compositions comprising a chelant

Also Published As

Publication number Publication date
WO2020227260A1 (fr) 2020-11-12
US11103482B2 (en) 2021-08-31
US20220273621A1 (en) 2022-09-01
KR20220084264A (ko) 2022-06-21
EP3965737A1 (fr) 2022-03-16
US20210015795A1 (en) 2021-01-21
KR102663319B1 (ko) 2024-05-03
AU2020268329A1 (en) 2022-01-06
US10799481B1 (en) 2020-10-13
JP2021191802A (ja) 2021-12-16
US20210137889A1 (en) 2021-05-13
KR102410503B1 (ko) 2022-06-17
US20240033250A1 (en) 2024-02-01
KR20200128629A (ko) 2020-11-16
US20210023222A1 (en) 2021-01-28
US20220257566A1 (en) 2022-08-18
IL287831A (en) 2022-01-01
CN111888326B (zh) 2023-07-21
JP2020183373A (ja) 2020-11-12
PE20220384A1 (es) 2022-03-18
CN117045596A (zh) 2023-11-14
US20200353083A1 (en) 2020-11-12
US11324722B2 (en) 2022-05-10
US11701343B2 (en) 2023-07-18
US20210386711A1 (en) 2021-12-16
MX2021013516A (es) 2022-01-24
BR112021022404A2 (pt) 2022-01-18
US11541036B2 (en) 2023-01-03
US10940138B2 (en) 2021-03-09
JP7141420B2 (ja) 2022-09-22
SG11202112272TA (en) 2021-12-30
CL2021002918A1 (es) 2022-08-19
CO2021015265A2 (es) 2022-02-28
US11311515B2 (en) 2022-04-26
US20210212992A1 (en) 2021-07-15
CN111888326A (zh) 2020-11-06
CA3139443A1 (fr) 2020-11-12
ZA202108950B (en) 2023-10-25
US10814001B1 (en) 2020-10-27
KR20240060580A (ko) 2024-05-08
US10898573B1 (en) 2021-01-26
US20230355587A1 (en) 2023-11-09

Similar Documents

Publication Publication Date Title
MA55895A (fr) Compositions d'oxymétazoline et procédés de traitement de troubles oculaires
MA51103A (fr) Compositions et procédés de traitement de l'atrophie musculaire et de la dystrophie myotonique
MA45798A (fr) Compositions et procédés d'inhibition de masp-3 pour le traitement de maladies et troubles divers
MA49069A (fr) Procédés et compositions pour le traitement d'apnée du sommeil
MA49045A (fr) Compositions et procédés destinés à la distribution régulée d'acide
MA52631A (fr) Compositions et méthodes pour le traitement de la maladie de parkinson
MA51916A (fr) Compositions pour le traitement de la dégénérescence maculaire liée à l'âge humide
MA50763A (fr) Compositions d'acides aminés et méthodés de traitement de maladies et troubles musculaires
MA52861A (fr) Méthodes et compositions pour le traitement de l'apnée du sommeil
MA53873A (fr) Compositions et procédés pour le traitement de la presbytie
MA56387A (fr) Dérivés de quinazoline-4-one utiles pour le traitement de maladies et de troubles associés à braf
MA54609A (fr) Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
MA50849A (fr) Substances et procédés pour le traitement d'hémoglobinopathies
MA51056A (fr) Compositions et méthodes pour le traitement d'affections métaboliques
MA54880A (fr) Compositions et procédés de traitement de troubles neurocognitifs
IL286636A (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES OR DISORDERS RELATED TO KRAS
MA54874A (fr) Compositions et procédés de traitement des troubles neurocognitifs
MA53741A (fr) Procédés de traitement de troubles myéloprolifératifs
MA56019A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA51628A (fr) Méthode de traitement de troubles de l'équilibre acido-basique
MA52961A (fr) Compositions et procédés pour la réduction ou le traitement d'une inflammation
MA45226A (fr) Compositions et méthodes de traitement ou de prévention d'affections liées à l'oxalate
MA55807A (fr) Méthodes de traitement ou de prévention de l'asthme par administration d'un antagoniste d'il-33
MA54792A (fr) Compositions et méthodes pour le traitement de la maladie de parkinson
MA49576A (fr) Compositions et méthodes pour le traitement d'infections fongiques